nedocromil

Nedocromil sodium is a chromone-class anti-inflammatory drug that stabilizes mast cell membranes, preventing calcium influx and subsequent degranulation. This blocks release of histamine, leukotrienes, and other mediators from mast cells and eosinophils, reducing both early and late-phase asthmatic responses to allergen exposure. It also has some inhibitory effects on eosinophils, neutrophils, and monocytes.

Clinically, nedocromil is used as a prophylactic controller medication for mild persistent asthma and exercise-induced bronchospasm, particularly in pediatric populations. It has no bronchodilator activity and provides no benefit during an acute asthma exacerbation—patients must be counseled that it is for prevention, not rescue. Onset of therapeutic effect may take days to weeks of regular use.

Side effects are generally mild and include unpleasant taste, cough, headache, and throat irritation from the inhaled formulation. It has a favorable safety profile compared to inhaled corticosteroids, lacking the growth suppression or adrenal suppression concerns, making it historically attractive for pediatric use.

However, nedocromil and cromolyn have largely fallen out of favor in current asthma management guidelines (GINA, NAEPP) due to their modest efficacy compared to inhaled corticosteroids and leukotriene receptor antagonists, along with the need for frequent dosing (typically 2-4 times daily) which affects compliance. It remains a testable concept for USMIE Step 1 primarily as an example of a mast cell stabilizer mechanism, often compared alongside cromolyn sodium in pharmacology questions about asthma treatment classes.